Alan qualified in medicine in 1984 from the University of Glasgow in Scotland.  He trained as a family doctor (GP) and worked in and around Glasgow for 14 years in the health service until leaving to join Novo Nordisk in 1998.

After leadership positions with both Novo Nordisk, BioMarin Europe and AstraZeneca, Alan joined Astellas as their UK Medical Director in 2009 before moving to a sub-regional European role in 2014.

In late 2016 he relocated to Singapore to become Head of Medical Affairs for Asia-Oceania and in 2020 his territories expanded to include Latin America, Middle East, Africa, Russia and Turkey.

In July 2021 Alan transferred back to the UK to lead medical affairs for Europe and Canada.

Alan is a Fellow of the Faculty of Pharmaceutical Medicine of the Royal College of Physicians (UK). Alan led a global medical affairs capability uplift programme at Astellas, he has a passion for leadership and team development and the ethics of pharmaceutical medicine.

Following Graduation in Medicine at the Free University Berlin, Michael pursued a career in General, Cardiovascular and Surgical Oncology in Germany and the UK, gaining an MD and an FRCS.  He joined pharmaceutical industry 25 years ago and has since been in clinical development, project leadership, and commercial and medical affairs roles at country, regional and global level. To date, Michael leads the Medical Affairs Team of Novartis Oncology, Region Europe.
Throughout his industry career, Michael mainly covered specialty care areas, e.g. Oncology and Immunology. He also qualified as a Pharmaceutical Physician and as an MBA. Research interests and publications are in Oncology and Immunology as well as in general aspects concerning Medical Affairs and Medicine Development in the Industry.

Daniél Vega Møller graduated in Medicine at the University of Copenhagen in 2000, where he also obtained his PhD within molecular cardio-genetics and heart failure. He has also been involved in the analysis of different biomarkers and their importance for prediction within the field of hypertension, CVD and obesity. After 10 years in the hospital setting in internal medicine, mainly cardiology, he moved to the pharma-industry and has been employed for more than 15 years focusing on drug development within the portfolio of insulin, obesity, liver health and metabolism, as well as Medial Affairs roles both at affiliate and regional level.

He is currently Vice President in the Strategic Operations of Novo Nordisk Health Care AG situated in the headquarter for international operations in Zürich, Switzerland. He is overall responsible for the Medical & Scientific Affairs activities focusing on cardiometabolic diseases like obesity, diabetes, cardio-vascular and chronic kidney diseases among others.

Olivia is an experienced leader working in the pharmaceutical industry for over 17 years, holding senior executive leadership positions throughout organizations of different sizes and in functions ranging from Patient Services, Medical Affairs, Marketing and Sales at local and international levels in Oncology, Rare Disease and Immunology.

She has managed products along the entire life-cycle with experience ranging from integrated evidence planning, Ph 3 go-to-market modeling through to management of loss of exclusivity .

She is a medical doctor with a Bachelor's Degree in Corporate Management and Entrepreneurship.

Also she holds a training in Healthcare System Transformation, experience as a DEI leader, and is a certified Coach.

Natasha Hansjee, PhD, is a global principal scientific communication director at Roche. She is also  an executive coach and a storyteller. She has over 20 years of pharmaceutical marketing experience: sales, local & global strategic product management; global product commercial strategy training; scientific communications; mentoring, coaching and facilitating - and has worked across all stages of the life cycle (early launch, launch, LoE). 

After receiving my medical degree from University Utrecht in the Netherlands, I became a general practitioner for 2 years at the Royal Netherlands Navy. After that assignment, I joined the biopharmaceutical industry with different positions and roles in Medical Affairs, working in medical education as well as developing and bringing new therapies to many patients. Through the years, I have had the opportunity and pleasure to meet physicians, patients and caregivers around the world to gain a better understanding of their real daily needs and challenges.

Since November 2016 at Ultragenyx, I am fully dedicated to Medical Affairs and Patient Advocacy activities around Europe, committed to bringing to market novel products for the treatment of rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. Having the opportunity of working so closely with Rare Disease patients, their caregivers and families enlightens my medical heart and makes me even more passionate about serving those in real need and helping them lead better lives.

Elizabeth Kupferer, PhD, WHNP-BC, is National Director of US Field Medical Affairs at Nestlé Health Science, where she leads field medical strategy for the gut microbiome portfolio, including a first-in-class oral live biotherapeutic for recurrent C. difficile infection. With extensive Medical Affairs leadership experience across the pharmaceutical, diagnostics, and device industries, and a track record of launching multiple first-in-class therapies at AbbVie, Novartis, Bausch Health, and Bayer, she brings deep expertise in building and leading high-performing MSL teams through complex scientific landscapes. A recognized thought leader in MSL professional development, Elizabeth is a member of the MSL Society Global Advisory Committee and a frequent speaker at Medical Affairs forums across the United States, Europe, and Asia. Her work centers on the evolving capabilities required of modern field medical professionals as they navigate precision medicine, emerging therapeutics, and an increasingly data-driven healthcare environment. Elizabeth holds a PhD from the University of Texas at Austin.

Arnas is paediatrician with passion for vaccination and strong believe in prevention as a key intervention that can improve public health. 

He obtained his MD degree in Lithuania, Vilnius University, in 1996. Prior graduating, he also completed a clerkship in University of Wisconsin-Madison, USA. 

Dr Arnas Berzanskis has more than 27 years of experience in Pharmaceutical Industry. He has worked in multiple local, regional, global roles across a variety of business departments (medical, clinical, commercial) which allows him to have a strategic view of the industry. 

Arnas is currently supervising a team of talented scientists and entrepreneurs who are reshaping the medical landscape towards improved healthcare and prevention. 

His recent scientific publications in peer review journals focus on burden of RSV in adults. 

Ron Weathermon, PharmD, is a seasoned Medical Affairs leader with more than 25 years of experience spanning global, regional, and local roles in the pharmaceutical industry. As Head of Innovation and Scientific Excellence at Teva Global Medical Affairs, he drives the development of forward-looking medical strategies, fosters cross-functional collaboration, and champions scientific innovation and governance across the organization. Prior to joining Teva, Ron served as Global Head of Medical Affairs Governance at Novartis, where he led large-scale organizational transformations, established a global governance framework, and expanded medical field capabilities. Recognized for his ability to align scientific excellence with business strategy, he has built and developed high-performing teams, enhanced medical compliance systems, and integrated medical functions across diverse therapeutic areas—advancing both innovation and operational rigor.

Following her graduation as Doctor in Veterinary Medicine and her specialization in tropical medicine at the Universite de Liege (Belgium), Pamela practiced as a veterinarian in zoos and several small animal practices.

She then began her career in the industry in Clinical Research as Clinical Research Associate then Program Manager in a contract research organization.

After leading the Scientific Communication at Mars/Royal Canin for Belgium and Luxemburg, she joined Takeda 10 years ago and has since held several positions in Medical Affairs at country, regional and global level. She is currently Global Medical Excellence Lead and takes care of developing and implementing Medical Affairs processes and capability building initiatives for the Medical colleagues across the organization, mainly around Insights Generation and Evidence Generation.
Throughout her industry career, Pamela mainly covered specialty care areas, e.g. Oncology and Immunology (GI).